Celsion Corporation Announces Strategic Loan Facility
28 juin 2018 08h30 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., June 28, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or “the Company”), an oncology drug development company, today announced that on June 27, 2018...
Celsion Corporation to Join Russell Microcap® Index
25 juin 2018 08h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., June 25, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that it will be added to the Russell Microcap® Index...
Celsion Corporation Reports First Quarter 2018 Financial Results and Provides Business Update
11 mai 2018 08h00 HE
|
Celsion Corporation
Significant Progress in Phase III Liver Cancer and Phase I/II Ovarian Cancer Studies Supported with Solid Fundamentals and a Strong Balance Sheet Company to Hold Conference...
Celsion Corporation to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference
08 mai 2018 08h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., May 08, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno, Chairman, President and Chief Executive Officer of Celsion, will...
Celsion Corporation to Hold First Quarter 2018 Financial Results Conference Call on Friday, May 11, 2018
04 mai 2018 09h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., May 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
International Liver Congress™ 2018 Symposium Highlights Celsion’s ThermoDox® in Treatment of Primary Liver Cancer
12 avr. 2018 08h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., April 12, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced a presentation and discussion of ThermoDox®,...
Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
09 avr. 2018 08h30 HE
|
Celsion Corporation
Blinded Progression-Free Survival (PFS) Rate in the OPTIMA Study is Consistent With the Subgroup Patient Population That Showed Benefit in the HEAT Study ThermoDox®-Highlighted Symposium, “Emerging...
Celsion Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results
27 mars 2018 08h30 HE
|
Celsion Corporation
Celsion Enters 2018 with Solid Fundamentals, a Strong Balance Sheet and an Advancing Clinical Pipeline Company to Hold Conference Call on Tuesday, March 27, 2018 at 11:00 a.m. EDT ...
Celsion Corporation to Hold Year-End 2017 Financial Results Conference Call on Tuesday, March 27, 2018
20 mars 2018 08h30 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., March 20, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year...
Celsion Corporation to Present at Upcoming Investor Conferences
12 mars 2018 08h00 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Tardugno, Chairman,...